Search
Tolbutamide
go.drugbank.com/drugs/DB01124ApprovedMedications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C18 SubstratesSynonyms: 1-Butyl-3-(p-tolylsulfonyl)urea, 1-p-Toluenesulfonyl-3-butylureaDutasteride
go.drugbank.com/drugs/DB01126ApprovedInvestigationalDutasteride is an oral synthetic 4-azasteroid commonly marketed under the trade name Avodart. It is a novel dual 5α-reductase inhibitor that works by blocking both isoforms of 5α-reductase enzymes in a potent, selective, and irreversible...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesCarvedilol
go.drugbank.com/drugs/DB01136ApprovedInvestigationalCarvedilol is a racemic mixture where the S(-) enantiomer is both a beta and alpha-1 adrenoceptor blocker, and the R(+) enantiomer is an alpha-1 adrenoceptor blocker. It is currently used to treat heart failure, left ventricular dysfunct...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesSulfinpyrazone
go.drugbank.com/drugs/DB01138ApprovedA uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties.
Categories: Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 SubstratesNefazodone
go.drugbank.com/drugs/DB01149ApprovedWithdrawnNefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury. Drug-induced hepatic i...
Categories: P-glycoprotein inducers, P-glycoprotein inhibitorsCrisaborole
go.drugbank.com/drugs/DB05219ApprovedInvestigationalCrisaborole is a novel oxaborole approved by FDA on December 14, 2016 as Eucrisa, a topical treatment of for mild to moderate atopic dermatitis. This non-steroidal agent is efficacious in improving disease severity, reducing the risk of ...
Categories: Cytochrome P-450 CYP2B6 Inhibitors, Cytochrome P-450 CYP2C8 InhibitorsCobimetinib
go.drugbank.com/drugs/DB05239ApprovedInvestigationalCobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been app...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesDexlansoprazole
go.drugbank.com/drugs/DB05351ApprovedDexlansoprazole is a new-generation proton pump inhibitor (PPI) used for the management of symptoms associated with gastroesophageal reflux disease (GERD) and erosive esophagitis. Dexlansoprazole is the R-enantiomer of DB00448, which is ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesBrivaracetam
go.drugbank.com/drugs/DB05541ApprovedInvestigationalBrivaracetam is a racetam derivative of levetiracetam used in the treatment of partial-onset seizures. Brivaracetam binds SV2A with 20 times higher affinity than levetiracetam . It is available under the brand name Briviact made by UCB. ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 SubstratesDovitinib
go.drugbank.com/drugs/DB05928InvestigationalDovitinib is an orally active small molecule that exhibits potent inhibitory activity against multiple RTKs involved in tumor growth and angiogenesis. Preclinical data show that dovitinib works to inhibit multiple kinases associated with...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 CYP1A2 Inducers